PDS Biotechnology Corp
PDSBHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 2:15 PM ET
0.9900-0.0400 (-3.88%)
2026-11-11 20:16 CET
Market cap
108.16 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-33.67 USD m
Free cash flow, TTM
-16.78 USD m
EPS diluted, TTM
-0.64
P/E
-
Price
PDSB against its 20, 50 and 200-day averages2050200earnings
44.7% under the 52-week high of 1.79 on 13 Oct 2026. 52-week low 0.20 on 19 Aug 2026. Last 15 sessions, 80.1% high to low
Profile
PDSB52-week range, 50% of the way up
0.201.79
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
| Employees | 21 |
|---|---|
| IPO | Oct 01, 2015 |
| Beta | 1.17 |
| ATR, 14d | 0.18 |
| Rel volume | 0.09 |
| Short float | 3.41% |
| Insider own | 1.73% |
| Inst own | 20.51% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 103.96M |
| Enterprise Value | 102.72M |
| Income | -33.67M |
| Sales | 0.00M |
| Book/sh | -0.06 |
| Cash/sh | 0.05 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 21 |
| IPO | Oct 01, 2015 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | - |
| P/C | 18.56 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 0.57 |
| Current Ratio | 0.57 |
| Debt/Eq | - |
| LT Debt/Eq | - |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | -0.64 |
|---|---|
| EPS next Y | -0.19 |
| EPS next Q | -0.09 |
| EPS this Y | 41.89% |
| EPS next Y | 55.81% |
| EPS next 5Y | 34.81% |
| EPS past 3/5Y | 19.55% 3.46% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 30.16% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 14.74% |
| Sales Q/Q | - |
| Earnings | Aug 13 BMO |
| EPS/Sales Surpr. | -38.46% - |
Ownership
| Insider Own | 1.73% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 20.51% |
| Inst Trans | 4.85% |
| ROA | -136.65% |
| ROE | -543.97% |
| ROIC | - |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | -18.42% |
| SMA50 | 3.39% |
| SMA200 | 17.87% |
| Trades | - |
Technical
| Shs Outstand | 105.00M |
|---|---|
| Shs Float | 103.19M |
| Short Float | 3.41% |
| Short Ratio | 0.14 |
| Short Interest | 3.52M |
| 52W High | 1.79 -44.69% |
| 52W Low | 0.20 407.17% |
| Volatility | 12.74% 17.07% |
| ATR (14) | 0.18 |
| RSI (14) | 44.10 |
| Beta | 1.17 |
| Rel Volume | 0.09 |
| Avg Volume | 25.60M |
| Volume | 1,807,558 |
Performance
| Perf Week | -23.85% |
|---|---|
| Perf Month | -38.13% |
| Perf Quarter | 324.53% |
| Perf Half Y | -25.56% |
| Perf YTD | 28.60% |
| Perf Year | -6.60% |
| Perf 3Y | -81.46% |
| Perf 5Y | -90.57% |
| Perf 10Y | -99.60% |
| Recom | 1.00 |
| Target Price | 4.50 |
| Prev Close | 1.03 |
| Price | 0.99 |
| Change % | -3.88% |
Analyst ratings
latest 6 of 6| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Nov 01, 2022 | Initiated | RB. Riley Securities | Buy | $10 | +910.1% |
| Jun 28, 2021 | Initiated | CCantor Fitzgerald | Overweight | $25 | +2,425.3% |
| Nov 10, 2020 | Upgrade | HH.C. Wainwright | Neutral → Buy | $6 | +506.1% |
| May 27, 2020 | Initiated | AAlliance Global Partners | Buy | $4 | +304.0% |
| Mar 09, 2020 | Initiated | NNoble Capital Markets | Outperform | $5.45 | +450.5% |
| Oct 24, 2019 | Initiated | CChardan Capital Markets | Buy | $10 | +910.1% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| INO | Inovio Pharmaceuticals Inc | 146.83M |
| BCAX | Bicara Therapeutics Inc | 709.09M |
| PGEN | Precigen Inc | 1.70B |
| ELTX | Elicio Therapeutics Inc | 43.87M |
| GLSI | Greenwich LifeSciences Inc | 240.82M |
| IMMP | Immutep Limited ADR | 27.05M |
| ONCY | Oncolytics Biotech Inc | 48.49M |
| ANIX | Anixa Biosciences Inc | 101.30M |
| MAIA | MAIA Biotechnology Inc | 64.22M |
| KURA | Kura Oncology Inc | 707.91M |
Held by
AUMNews
latest 14 of 198- PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds (GlobeNewswire)
- PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors (GlobeNewswire)
- PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases (GlobeNewswire) -12.92%
- KOD Stock Cracks Septembers Top 5 Biotech Gainers On Eye Drug Win But Pharma Bro Shkreli Says It Still Sucks (Stocktwits)
- PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology (GlobeNewswire) +8.09%
- This Tiny Biotech Is Beating MRNA, IOVA And SLS Here's How A Billionaire Fueled Its September Rally (Stocktwits) -14.98%
- IBRX Stock Gains As Soon-Shiongs Nant Capital Backs Second Cancer-Immunotherapy Bet (Stocktwits) +35.33% +46.65%
- PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors (GlobeNewswire)
- PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks (GlobeNewswire) +36.36%
- PDS Biotechnology: Q2 Earnings Snapshot (Associated Press)
- PDS Biotech Reports Second Quarter 2026 Financial Results (GlobeNewswire)
- PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 (GlobeNewswire) -64.87%
- PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com) +20.91% +7.52%
- PDS Biotechnology: Q1 Earnings Snapshot (Associated Press)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-08-13 | -0.180 | -0.130 | -0.180 | 0.00 | 0.00 | 2 |
| 2026Q1 | 2026-05-13 | -0.130 | -0.140 | -0.132 | 0.00 | 0.00 | 2 |
| 2025Q4 | 2026-03-30 | -0.130 | -0.200 | -0.141 | 0.00 | 0.00 | 1 |
| 2025Q3 | 2025-11-13 | -0.190 | -0.197 | -0.192 | 0.00 | 0.00 | 3 |
| 2025Q2 | 2025-08-13 | -0.210 | -0.233 | -0.206 | 0.00 | 0.00 | 3 |
| 2025Q1 | 2025-05-14 | -0.210 | -0.247 | -0.210 | 0.00 | 0.00 | 3 |
| 2024Q4 | 2025-03-27 | -0.210 | -0.277 | -0.210 | 0.00 | 0.00 | 3 |
| 2024Q3 | 2024-11-14 | -0.290 | -0.297 | -0.291 | 0.00 | 0.00 | 6 |
| 2024Q2 | 2024-08-13 | -0.230 | -0.327 | -0.227 | 0.00 | 0.00 | 6 |
| 2024Q1 | 2024-05-15 | -0.300 | -0.367 | -0.305 | 0.00 | 0.00 | 6 |
| 2023Q4 | 2024-03-27 | -0.350 | -0.439 | -0.344 | 0.00 | 0.00 | 7 |
| 2023Q3 | 2023-11-14 | -0.350 | -0.446 | -0.351 | 0.00 | 0.00 | 7 |
| 2023Q2 | 2023-08-14 | -0.370 | -0.347 | -0.375 | 0.00 | 0.00 | 7 |
| 2023Q1 | 2023-05-15 | -0.320 | -0.300 | -0.318 | 0.00 | 0.00 | 7 |
| 2022Q4 | 2023-03-28 | -0.650 | -0.287 | -0.665 | 0.00 | 0.00 | 7 |
| 2022Q3 | 2022-11-14 | -0.260 | -0.281 | -0.261 | 0.00 | 0.00 | 7 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2019FY | -1.440 | -1.393 | -1.438 | 0.00 | 0.00 |
| 2020FY | -0.890 | -0.883 | -0.887 | 0.00 | 0.00 |
| 2021FY | -0.660 | -0.737 | -0.661 | 0.00 | 0.00 |
| 2022FY | -1.430 | -1.083 | -1.429 | 0.00 | 0.00 |
| 2023FY | -1.390 | -1.457 | -1.387 | 0.00 | 0.00 |
| 2024FY | -1.030 | -1.110 | -1.032 | 0.00 | 0.00 |
| 2025FY | -0.740 | -0.800 | -0.740 | 0.00 | 0.00 |
| 2026FY | - | -0.430 | - | - | 0.00 |
| 2027FY | - | -0.190 | - | - | 9.38 |
| 2028FY | - | -0.205 | - | - | 1.90 |
| 2029FY | - | -0.130 | - | - | 30.77 |
| 2030FY | - | -0.040 | - | - | 75.66 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | S | 2026-10-27 | 2 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-08-13 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-05-13 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-03-30 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | R | 2025-11-13 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-11 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-10 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-09 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-08 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-07 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-06 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-05 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-04 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | R | 2025-11-03 | 1 | 0 | 0 | -0.17 | -0.17 | -0.17 |
Estimate history
| EPS, annual | -33.4 | -22.991 | -1.438 | -0.887 | -0.661 | -1.429 | -1.387 | -1.032 | -0.744 | -0.6403 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -0.227 | -0.291 | -0.21 | -0.21 | -0.206 | -0.192 | -0.141 | -0.132 | -0.175 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
| Shares, annual | 1.543 | 0.171 | 5.281 | 22.262 | 28.449 | 30.17 | 33.095 | 37.987 | 54.878 | 55.922 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 36.779 | 36.82 | 37.987 | 45.446 | 46.633 | 47.705 | 54.878 | 55.816 | 55.922 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.25 | 0.18 | 0.10 | 0.07 |
| Gross Profit | -0.06 | -0.06 | -0.06 | -0.06 | -0.05 | -0.25 | -0.18 | -0.10 | -0.07 |
| Selling, General and Administrative Excl. Other | 27.77 | 31.48 | 36.26 | 42.99 | 41.62 | 21.19 | 14.73 | 15.41 | 3.58 |
| Research and Development | 15.70 | 19.03 | 22.57 | 27.76 | 29.43 | 11.25 | 7.92 | 6.10 | 0.83 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.83 | -31.54 | -36.32 | -43.05 | -41.67 | -21.44 | -14.90 | -15.51 | -3.65 |
| Interest Expense | 6.66 | 5.34 | 4.67 | 4.21 | 1.32 | 0.00 | 0.00 | 0.03 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.81 | 0.19 |
| Net Income Before Taxes | -33.67 | -35.67 | -38.48 | -44.35 | -42.05 | -21.43 | -14.85 | -7.38 | -3.84 |
| Income Taxes | 0.00 | -1.17 | -0.87 | -1.41 | -1.20 | -4.52 | 0.00 | -0.38 | 0.00 |
| Consolidated Net Income | -33.67 | -34.50 | -37.61 | -42.94 | -40.85 | -16.92 | -14.85 | -7.00 | -3.84 |
| Net Income From Continuing Operations | -33.67 | -34.50 | -37.61 | -42.94 | -40.85 | -16.92 | -14.85 | -7.00 | -3.84 |
| Net Income | -33.67 | -34.50 | -37.61 | -42.94 | -40.85 | -16.92 | -14.85 | -7.00 | -3.84 |
| EPS (Recurring) | -0.60 | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | -2.56 | -22.21 |
| EPS (Basic, Before Extraordinaries) | -0.64 | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | -22.99 |
| EPS (Diluted) | -0.64 | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | -22.99 |
| EBITDA | -27.77 | -31.48 | -36.26 | -42.99 | -41.62 | -21.19 | -14.73 | -15.41 | -3.58 |
| Non-Operating Income (Expense) | 0.82 | 1.22 | 2.51 | 2.90 | 0.94 | 0.00 | 0.06 | 0.35 | -0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 4.69 | 3.24 | 5.41 | 6.02 | 4.10 | 4.07 | 0.43 | 2.29 | 0.25 |
| Shares Outstanding | 55.92 | 54.88 | 37.99 | 33.09 | 30.17 | 28.45 | 22.26 | 5.28 | 0.17 |
| Market Capitalization | 108.16 | 108.16 | 60.98 | 154.61 | 376.31 | 230.35 | 47.64 | 15.31 | 10.10 |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Gross Profit | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Selling, General and Administrative Excl. Other | 6.48 | 6.51 | 6.66 | 8.13 | 7.61 | 9.09 | 7.35 | 10.16 |
| Research and Development | 3.27 | 3.46 | 4.41 | 4.58 | 4.21 | 5.83 | 4.53 | 6.80 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.50 | -6.52 | -6.67 | -8.14 | -7.62 | -9.11 | -7.36 | -10.18 |
| Interest Expense | 3.38 | 1.01 | 1.11 | 1.15 | 2.14 | 0.93 | 1.10 | 1.21 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -9.75 | -7.35 | -7.56 | -9.01 | -9.43 | -9.66 | -7.95 | -10.73 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.17 | 0.00 | 0.00 |
| Consolidated Net Income | -9.75 | -7.35 | -7.56 | -9.01 | -9.43 | -8.49 | -7.95 | -10.73 |
| Net Income From Continuing Operations | -9.75 | -7.35 | -7.56 | -9.01 | -9.43 | -8.49 | -7.95 | -10.73 |
| Net Income | -9.75 | -7.35 | -7.56 | -9.01 | -9.43 | -8.49 | -7.95 | -10.73 |
| EPS (Recurring) | -0.18 | -0.13 | -0.14 | -0.19 | -0.21 | -0.21 | -0.21 | -0.29 |
| EPS (Basic, Before Extraordinaries) | -0.18 | -0.13 | -0.14 | -0.19 | -0.21 | -0.21 | -0.21 | -0.29 |
| EPS (Diluted) | -0.18 | -0.13 | -0.14 | -0.19 | -0.21 | -0.21 | -0.21 | -0.29 |
| EBITDA | -6.48 | -6.51 | -6.66 | -8.13 | -7.61 | -9.09 | -7.35 | -10.16 |
| Non-Operating Income (Expense) | 0.13 | 0.19 | 0.22 | 0.28 | 0.33 | 0.38 | 0.50 | 0.67 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.13 | 1.16 | 1.16 | 1.25 | 0.45 | 0.99 | 1.64 | 1.78 |
| Shares Outstanding | 55.92 | 55.82 | 54.88 | 47.71 | 46.63 | 45.45 | 37.99 | 36.82 |
| Market Capitalization | 108.16 | 33.11 | 42.12 | 47.50 | 60.79 | 53.06 | 60.98 | 140.65 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 26.71 | 41.69 | 56.56 | 73.82 | 65.24 | 28.84 | 12.16 | 0.10 | 88.07 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.54 | 3.36 | 2.49 | 2.66 | 1.60 | 1.50 | 2.31 | 0.02 | 0.99 |
| Total Current Assets | 28.25 | 45.05 | 59.06 | 76.48 | 66.84 | 30.34 | 14.47 | 0.12 | 89.05 |
| Net Property, Plant & Equipment | 0.24 | 0.30 | 0.34 | 0.53 | 0.36 | 0.55 | 0.02 | 0.03 | 3.42 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Deferred Tax Assets | 0.03 | - | - | - | - | - | - | - | - |
| Other Assets | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.14 |
| Total Assets | 30.53 | 45.36 | 59.39 | 77.01 | 67.20 | 30.89 | 14.49 | 0.16 | 92.62 |
| Short Term Debt Incl. Current Port. of LT Debt | 5.17 | 12.56 | 4.22 | 0.29 | 0.26 | 0.12 | 0.00 | 0.00 | 3.08 |
| Accounts Payable | 3.57 | 1.68 | 6.98 | 1.22 | 1.31 | 1.42 | 1.20 | 1.31 | 0.00 |
| Other Current Liabilities | 0.74 | 2.84 | 2.42 | 8.31 | 2.19 | 1.74 | 1.60 | 0.60 | 9.79 |
| Total Current Liabilities | 9.48 | 17.09 | 13.63 | 9.82 | 3.76 | 3.27 | 2.79 | 1.91 | 12.87 |
| Long Term Debt | 11.76 | 9.27 | 19.63 | 23.18 | 0.23 | 0.49 | 0.00 | 0.03 | 17.38 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.00 |
| Deferred Tax Liabilities | 0.03 | - | - | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 21.28 | 26.35 | 33.26 | 33.01 | 3.99 | 3.76 | 2.79 | 2.23 | 30.25 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 9.25 | 19.00 | 26.13 | 44.00 | 63.21 | 27.13 | 11.70 | -2.07 | 62.37 |
| Total Shareholders Equity | 9.25 | 19.00 | 26.13 | 44.00 | 63.21 | 27.13 | 11.70 | -2.07 | 62.37 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 9.25 | 19.00 | 26.13 | 44.00 | 63.21 | 27.13 | 11.70 | -2.07 | 62.37 |
| Total Liabilities & Stockholders Equity | 30.53 | 45.36 | 59.39 | 77.01 | 67.20 | 30.89 | 14.49 | 0.16 | 92.62 |
| Book Value Per Share | 0.17 | 0.50 | 0.79 | 1.46 | 2.22 | 1.22 | 2.21 | -12.09 | 40.41 |
| Tangible Book Value Per Share | 0.17 | 0.50 | 0.79 | 1.46 | 2.22 | 1.22 | 2.21 | -12.09 | 40.41 |
| Full-Time Employees | 21 | 24 | 25 | 26 | 22 | 15 | 20 | 10 | 38 |
| Price to Book Ratio | -16.09 | 2.73 | 6.29 | 7.98 | 3.65 | 1.76 | 1.20 | 0.34 | 3.87 |
| Return on Assets | -90.91 | -71.81 | -62.97 | -56.66 | -34.50 | -65.43 | -27.60 | -8.27 | -49.98 |
| Return on Equity | -244.16 | -166.65 | -122.46 | -76.21 | -37.46 | -76.48 | -33.70 | -12.72 | -67.08 |
| Return on Invested Capital | -164.18 | -133.03 | -93.84 | -60.81 | -26.67 | -53.76 | -59.83 | - | -63.77 |
| Quick Ratio | 2.98 | 2.64 | 4.33 | 7.79 | 17.80 | 9.28 | 5.18 | 0.06 | 6.92 |
| Current Ratio | 2.98 | 2.64 | 4.33 | 7.79 | 17.80 | 9.28 | 5.18 | 0.06 | 6.92 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -33.67 | -34.50 | -37.61 | -42.94 | -40.85 | -16.92 | -14.85 | -7.00 | -3.84 |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.25 | 0.18 | 0.10 | 0.07 |
| Other Funds (Non Cash) | 9.43 | 7.07 | 8.27 | 9.45 | 10.62 | 4.11 | 0.45 | -6.19 | 1.05 |
| Funds from Operations | -24.18 | -27.37 | -29.28 | -33.44 | -30.18 | -12.56 | -14.22 | -13.47 | -2.71 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 7.40 | -0.38 | -5.75 | -0.20 | 4.47 | 0.08 | 1.07 | -4.60 | 1.15 |
| Cash from Operating Activities | -16.78 | -27.75 | -35.03 | -33.64 | -25.71 | -12.49 | -13.15 | -18.07 | -1.57 |
| Capital Expenditures | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.11 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 29.38 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -8.84 | 20.34 | 23.37 | 16.44 | 10.01 | 48.89 | 29.83 | 0.75 | 1.51 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | -8.84 | 20.34 | 23.37 | 16.44 | 10.01 | 48.89 | 29.83 | 0.75 | 1.51 |
| Proceedsfrom Stock Options | -16.25 | 13.98 | 22.60 | 16.13 | 9.86 | 48.54 | 29.76 | 0.75 | 1.28 |
| Issuance or Reduction of Debt, Net | -0.66 | -7.56 | -3.18 | -0.06 | 24.55 | 0.00 | 0.00 | 0.00 | -0.02 |
| Change in Long Term Debt | -0.66 | -7.56 | -3.18 | -0.06 | 24.55 | 0.00 | 0.00 | 0.00 | -0.02 |
| Issuance of Long Term Debt | 22.49 | 18.16 | 0.00 | 0.00 | 24.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -23.14 | -25.73 | -3.18 | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | -0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -9.49 | 12.77 | 20.19 | 16.38 | 34.29 | 48.89 | 29.83 | 0.75 | 1.50 |
| Net Change in Cash | -26.28 | -14.98 | -14.87 | -17.26 | 8.58 | 36.40 | 16.68 | 12.06 | -0.07 |
| Free Cash Flow | -16.78 | -27.75 | -35.06 | -33.64 | -25.71 | -12.49 | -13.15 | -18.07 | -1.57 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.38 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 5.60 | 21.66 | 26.71 | 26.20 | 31.87 | 39.98 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.45 | 1.23 | 1.54 | 1.69 | 1.77 | 2.49 |
| Total Current Assets | 7.05 | 22.89 | 28.25 | 27.89 | 33.65 | 42.47 |
| Net Property, Plant & Equipment | 0.21 | 0.23 | 0.24 | 0.26 | 0.27 | 0.29 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | - | - | 0.03 | - | - | - |
| Other Assets | 1.55 | 1.55 | 2.00 | 6.55 | 6.55 | 4.27 |
| Total Assets | 8.81 | 24.66 | 30.53 | 34.71 | 40.48 | 47.03 |
| Short Term Debt Incl. Current Port. of LT Debt | 4.35 | 5.24 | 5.17 | 6.04 | 5.55 | 12.56 |
| Accounts Payable | 6.39 | 3.65 | 3.57 | 5.18 | 4.50 | 2.86 |
| Other Current Liabilities | 1.63 | 1.26 | 0.74 | 2.10 | 1.48 | 2.85 |
| Total Current Liabilities | 12.38 | 10.15 | 9.48 | 13.33 | 11.53 | 18.27 |
| Long Term Debt | 0.01 | 10.62 | 11.76 | 11.92 | 12.98 | 6.40 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | 0.03 | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 12.39 | 20.77 | 21.28 | 25.25 | 24.52 | 24.67 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -3.58 | 3.89 | 9.25 | 9.45 | 15.96 | 22.36 |
| Total Shareholders Equity | -3.58 | 3.89 | 9.25 | 9.45 | 15.96 | 22.36 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -3.58 | 3.89 | 9.25 | 9.45 | 15.96 | 22.36 |
| Total Liabilities & Stockholders Equity | 8.81 | 24.66 | 30.53 | 34.71 | 40.48 | 47.03 |
| Book Value Per Share | -0.06 | 0.07 | 0.17 | 0.20 | 0.34 | 0.49 |
| Tangible Book Value Per Share | -0.06 | 0.07 | 0.17 | 0.20 | 0.34 | 0.49 |
| Full-Time Employees | - | - | 21 | - | - | - |
| Price to Book Ratio | -16.09 | 3.59 | 3.88 | 2.95 | 2.70 | 2.38 |
| Return on Assets | -136.65 | -93.05 | -90.91 | -80.05 | -72.50 | -61.18 |
| Return on Equity | -543.97 | -254.09 | -244.16 | -221.81 | -156.16 | -119.22 |
| Return on Invested Capital | - | -50.63 | -36.00 | -42.15 | -32.59 | -29.51 |
| Quick Ratio | 0.57 | 2.26 | 2.98 | 2.09 | 2.92 | 2.33 |
| Current Ratio | 0.57 | 2.26 | 2.98 | 2.09 | 2.92 | 2.33 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Net Income | -9.75 | -7.35 | -7.56 | -9.01 | -9.43 | -8.49 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Other Funds (Non Cash) | 4.05 | 1.61 | 2.08 | 1.69 | 1.56 | 1.73 |
| Funds from Operations | -5.68 | -5.73 | -5.47 | -7.30 | -7.86 | -6.74 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 2.89 | 1.36 | 1.76 | 1.39 | -1.24 | -2.29 |
| Cash from Operating Activities | -2.79 | -4.37 | -3.70 | -5.92 | -9.10 | -9.03 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 1.15 | 0.83 | 7.16 | -17.98 | 20.70 | 10.46 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.15 | 0.83 | 7.16 | -17.98 | 20.70 | 10.46 |
| Proceedsfrom Stock Options | 0.10 | 0.83 | 0.80 | -17.98 | 20.70 | 10.46 |
| Issuance or Reduction of Debt, Net | -14.42 | -1.51 | -2.94 | 18.22 | -19.70 | -3.14 |
| Change in Long Term Debt | -14.42 | -1.51 | -2.94 | 18.22 | -19.70 | -3.14 |
| Issuance of Long Term Debt | 4.32 | 0.00 | -1.07 | 19.24 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -18.75 | -1.51 | -1.87 | -1.02 | -19.70 | -3.14 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -13.27 | -0.68 | 4.22 | 0.24 | 1.00 | 7.32 |
| Net Change in Cash | -16.06 | -5.05 | 0.51 | -5.67 | -8.11 | -1.71 |
| Free Cash Flow | -2.79 | -4.37 | -3.70 | -5.92 | -9.10 | -9.03 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 3.41% | 3.5M | 103.2M | 25.18M |
| 2026-10-15 | 3.28% | 3.4M | 103.2M | 23.91M |
| 2026-09-30 | 5.04% | 2.8M | 55.0M | 21.51M |
| 2026-09-15 | 11.65% | 6.4M | 55.0M | 16.79M |
| 2026-08-31 | 4.27% | 2.3M | 55.0M | 1.30M |
| 2026-08-14 | 3.44% | 1.9M | 55.0M | 1.22M |
| 2026-07-31 | 3.34% | 1.8M | 55.0M | 692.38K |
| 2026-07-15 | 2.97% | 1.6M | 55.0M | 847.39K |
| 2026-06-30 | 2.44% | 1.3M | 54.9M | 1.02M |
| 2026-06-15 | 2.75% | 1.5M | 54.4M | 1.03M |
| 2026-05-29 | 3.23% | 1.8M | 54.4M | 907.26K |
| 2026-05-15 | 3.39% | 1.8M | 54.4M | 800.97K |
| 2026-04-30 | 3.14% | 1.7M | 54.4M | 728.43K |
| 2026-04-15 | 3.16% | 1.7M | 54.4M | 700.15K |
| 2026-03-31 | 3.77% | 2.1M | 54.4M | 607.01K |
| 2026-03-13 | 3.82% | 2.0M | 53.3M | 572.72K |
| 2026-02-27 | 5.04% | 2.7M | 53.3M | 660.54K |
| 2026-02-13 | 4.54% | 2.4M | 53.3M | 674.47K |
| 2026-01-30 | 4.11% | 2.2M | 53.3M | 807.55K |
| 2026-01-15 | 4.08% | 2.2M | 53.3M | 852.32K |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 0.50 | 0.20 | 0.70 | 0.52 | 21.052 | 13.00 | 0.00 | 0.883 | -0.052 | 0.000 |
| call | 1.00 | 0.00 | 0.10 | 0.10 | 3.438 | 62.00 | 2.00 | 0.550 | -0.026 | 0.000 |
| call | 1.50 | 0.00 | 0.05 | 0.04 | 5.381 | 69.00 | 2.00 | 0.242 | -0.032 | 0.000 |
| call | 2.00 | 0.00 | 0.60 | 0.05 | 8.337 | 17.00 | 0.00 | 0.195 | -0.043 | 0.000 |
| call | 2.50 | 0.00 | 0.75 | 0.00 | 9.760 | 0.00 | 0.00 | 0.175 | -0.047 | 0.000 |
| call | 3.00 | 0.00 | 0.75 | 0.01 | 10.942 | 11.00 | 0.00 | 0.163 | -0.051 | 0.000 |
| put | 0.50 | 0.00 | 0.75 | 0.00 | 14.078 | 0.00 | 0.00 | -0.117 | -0.052 | 0.000 |
| put | 1.00 | 0.05 | 0.10 | 0.13 | 5.303 | 1,469 | 10.00 | -0.424 | -0.032 | 0.000 |
| put | 1.50 | 0.10 | 0.85 | 0.50 | 16.710 | 1.00 | 2.00 | -0.763 | -0.035 | 0.000 |
| put | 2.00 | 0.90 | 1.20 | 1.17 | 24.562 | 0.00 | 2.00 | -0.805 | -0.041 | 0.000 |
| put | 2.50 | 1.10 | 1.85 | 0.00 | 20.834 | 0.00 | 0.00 | -0.825 | -0.045 | 0.000 |
| put | 3.00 | 1.60 | 2.35 | 0.00 | 21.989 | 0.00 | 0.00 | -0.838 | -0.047 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | 8-K | Current report | 2026-11-09 | SEC |
| 2026-10-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-18 | SEC |
| 2026-10-21 | 3 | Initial statement of beneficial ownership of securities | 2026-10-18 | SEC |
| 2026-10-21 | 8-K | Current report | 2026-10-20 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-18 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-18 | SEC |
| 2026-10-20 | 3 | Initial statement of beneficial ownership of securities | 2026-10-18 | SEC |
| 2026-10-20 | 3 | Initial statement of beneficial ownership of securities | 2026-10-18 | SEC |
| 2026-10-20 | 8-K | Current report | 2026-10-18 | SEC |
| 2026-10-14 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-10-06 | 8-K | Current report | 2026-10-06 | SEC |
| 2026-09-22 | 8-K | Current report | 2026-09-22 | SEC |
| 2026-09-21 | SCHEDULE 13D | SEC | ||
| 2026-09-21 | 3 | Initial statement of beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-21 | 3 | Initial statement of beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-21 | 8-K | Current report | 2026-09-21 | SEC |
| 2026-09-18 | 3 | Initial statement of beneficial ownership of securities | 2026-09-12 | SEC |
| 2026-09-14 | 8-K | Current report | 2026-09-12 | SEC |
| 2026-09-08 | 8-K | Current report | 2026-09-07 | SEC |
| 2026-09-04 | 8-K | Current report | 2026-08-31 | SEC |
| 2026-08-25 | 8-K | Current report | 2026-08-21 | SEC |
| 2026-08-19 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-08-14 | 8-K | Current report | 2026-08-10 | SEC |
| 2026-08-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-08-11 | 8-K | Current report | 2026-08-11 | SEC |
| 2026-07-31 | 8-K | Current report | 2026-07-30 | SEC |
| 2026-07-21 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-07-21 | 424B4 | SEC | ||
| 2026-07-10 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 3.04% |
| Focus Partners Wealth | 1.15% |
| Quantinno Capital Management LP | 1.15% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.10% |
| BlackRock, Inc. | 1.09% |
| VANGUARD FIDUCIARY TRUST CO | 0.64% |
| Militia Capital Management LLC | 0.59% |
| CITADEL ADVISORS LLC | 0.58% |
| MORGAN STANLEY | 0.56% |
| BLAIR WILLIAM & CO/IL | 0.54% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.87% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.05% |
| Fidelity Extended Market Index Fund | 0.52% |
| iShares Micro-Cap ETF | 0.34% |
| Fidelity Total Market Index Fund | 0.17% |
| Fidelity Series Total Market Index Fund | 0.15% |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND | 0.09% |
| Fidelity Nasdaq Composite Index Fund | 0.05% |
| VANGUARD BALANCED INDEX FUND | 0.05% |
| 1290 VT Micro Cap Portfolio | 0.02% |
OakChart. PDSB. Cached 15 minutes.
Some panels did not load: insider.